Perspective Therapeutics’ Post

📰An article was just published on novel preclinical models #organoids. The joint research study by CTIBiotech, Transgene and Medical university of Plovdiv kept alive for the longest time ever recorded in vitro, three-dimensional Bioprinted microtumors manufactured from patient’s primary tumors. This study allowed a screening of Transgene’s #OncolyticViruses🦠 and realistic modelization of metastatic colorectal cancer. https://lnkd.in/gRcftByf

💥CAR-T for neuroblastoma 🔶How do you address neuroblastoma, the leading extracranial solid tumor in kids, using CAR-T cells? 🔶The team including Elisa Bergaggio and Roberto Chiarle has recently explored using CAR-T targeting the ALK receptor in neuroblastoma preclinical models. 🔶Notably, the effectiveness of ALK-specific CAR-T is boosted by ALK inhibitors, partly due to their role in upping ALK target surface expression. 🔶This approach shows promise in tackling neuroblastoma, responsible for 12-15% of cancer fatalities in children. https://lnkd.in/gghhpVyt https://lnkd.in/gcP2vwba

[Paper Highlight] Congratulations to Marc, Isma and Elodie from our translational pharmacology department for this new scientific publication on Breast Cancer models! 📃 "Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models" Read the paper here 👇 https://ow.ly/Csna50QvM7p #Oncology #Models #BreastCancer #CRO #OncodesignServices

Researchers are investigating nanoparticle-based drug delivery for enhanced ovarian cancer treatment. Overcoming challenges associated with traditional chemotherapy, nanoparticles offer precise drug delivery, minimizing side effects. Various nanoparticle types, including organic and inorganic variants, demonstrate improved stability and specific tumor targeting. Active mechanisms, such as aptamer binding, contribute to enhanced targeting precision. Despite ongoing research, nanoparticle-based drug delivery holds promise as an innovative and efficient approach for ovarian cancer treatment with minimal side effects. Read more: https://lnkd.in/dQJAFmci #aptamer #research #oncology #medical #biology

A research study published in the journal 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 reports the succesfull application of a p53 mRNA system for the therapy of high-grade serous ovarian carcinomas (OC), an aggressive cancer which exhibits high rates of tumor suppressor TP53 mutations.  https://lnkd.in/dYQdsbNJ #oncology #biomedicalresearch #medicine #lifescience #ovariancarninomas

Are you an #oncology researcher looking for the right model for your next study? Our new SRG (Sprague Dawley, Rag2-, Il2rg-) rat is an ideal alternative research model to mice in certain preclinical oncology applications. Learn more about this model in our whitepaper including research applications & tumor growth kinetics. https://okt.to/9HBNzU

#News 🎉Recently, researchers from China published the research paper “ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion” in the journal Cell, which showed that the role of ITPRIPL1 (or CD3L1, CD3ε ligand 1) in impeding T cell activation during the critical “signal one” phase. 🎯This discovery positions CD3L1 as a promising therapeutic target against multiple tumor types. 👉Check out our CD3 products: https://lnkd.in/gdxitXfR 📧 [email protected]  #celllinedevelopment #cancertreatment #drugdiscovery #antibody #Oncology

A recent workshop summed up the state of play for circulating tumor DNA. Although evidence is building of its utility as a biomarker in many oncology settings, its prognostic value has yet to be proven. Read more here: https://bit.ly/44FadqQ #AgencyIQ #LifeSciences #Regulatory #Oncology

Are you an #oncology researcher looking for the right model for your next study? Our new SRG (Sprague Dawley, Rag2-, Il2rg-) rat is an ideal alternative research model to mice in certain preclinical oncology applications. Learn more about this model in our whitepaper including research applications & tumor growth kinetics. https://okt.to/Zv0lVK